KIR3DL2 is a useful biomarker and therapeutic target to prevent and treat a subset of cutaneous and non-cutaneous peripheral T-cell lymphomas, respectively

摘要

The present invention relates to a ligand molecule that specifically binds to KIR3DL2 on the surface of KIR3DL2-expressing malignant T cells for the treatment of lymphoma. The invention also relates to the in vitro use of KIR3DL2 expression levels as a biomarker useful for diagnosing and / or monitoring lymphoma.